Literature DB >> 2971083

Hypotensive effect of taurine. Possible involvement of the sympathetic nervous system and endogenous opiates.

T Fujita1, Y Sato.   

Abstract

We studied the role of diminished sympathetic nervous system (SNS) activity and endogenous opiate activation in the hypotensive action of taurine, a sulfur amino acid, in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Supplementation of taurine could prevent the development of DOCA-salt hypertension in rats, but failed to change blood pressure in vehicle-treated control rats. Cardiac NE turnover, which was determined from the rate of decline of tissue NE concentration after the administration of alpha-methyl-p-tyrosine, was markedly accelerated in DOCA-salt rats, but 1% taurine supplement restored it to normal. Moreover, naloxone (2 mg/kg), the specific opiate antagonist, increased blood pressure in taurine-treated DOCA-salt rats, restoring it to levels similar to those in the DOCA-salt rats. In contrast, taurine did not decrease cardiac NE turnover in the control rats, nor did naloxone increase blood pressure in the taurine-treated control rats. Moreover, supplementation of taurine increased both beta-endorphin-like immunoreactive material and taurine contents in the hypothalamus of DOCA-salt rats, whereas it did not increase beta-endorphin in that of control rats despite increased taurine contents. Thus, taurine not only normalized the increased cardiac SNS activity but also elicited an opiate-mediated vasodepressor response only in DOCA-salt rats. It is suggested, therefore, that endogenous opiate activation, which is intimately related to SNS suppression, may contribute to the antihypertensive effect of taurine in sodium chloride hypertension.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971083      PMCID: PMC303613          DOI: 10.1172/JCI113709

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Effects of taurine and gamma-aminobutyric acid on akinesia and analgesia induced by D-Ala2-Met-enkephalinamide in rats.

Authors:  K Izumi; E Munekata; H Yamamoto; T Nakanishi; A Barbeau
Journal:  Peptides       Date:  1980       Impact factor: 3.750

2.  Possible involvement of an endogenous opioid in the antihypertensive effect of clonidine in patients with essential hypertension.

Authors:  C Farsang; J Kapocsi; I Juhasz; G Kunos
Journal:  Circulation       Date:  1982-12       Impact factor: 29.690

3.  Dietary calcium in human hypertension.

Authors:  D A McCarron; C D Morris; C Cole
Journal:  Science       Date:  1982-07-16       Impact factor: 47.728

4.  Possible role of nutritional factors in the incidence of cerebral lesions in stroke-prone spontaneously hypertensive rats.

Authors:  Y Yamori; R Horie; H Tanase; K Fujiwara; Y Nara; W Lovenberg
Journal:  Hypertension       Date:  1984 Jan-Feb       Impact factor: 10.190

5.  Differential cardiovascular effects of mu, delta and kappa opiate agonists at discrete hypothalamic sites in the anesthetized rat.

Authors:  G Feuerstein; A I Faden
Journal:  Life Sci       Date:  1982 Nov 15-22       Impact factor: 5.037

6.  Hypotensive effect of fasting: possible involvement of the sympathetic nervous system and endogenous opiates.

Authors:  D Einhorn; J B Young; L Landberg
Journal:  Science       Date:  1982-08-20       Impact factor: 47.728

7.  In vivo and in vitro effects of substance P on the release of beta-endorphin-like immunoreactivity.

Authors:  M Matsumura; A Yamanoi; S Yamamoto; S Saito
Journal:  Neuroendocrinology       Date:  1982       Impact factor: 4.914

8.  Cardiovascular and respiratory effects of beta-endorphin in anesthetized and conscious rats.

Authors:  J M Sitsen; J M Van Ree; W De Jong
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

9.  Effects of taurine on tolerance to [D-Ala2, Met5]enkephalinamide in rats.

Authors:  K Izumi; E Munekata; A Barbeau; T Nakanishi; M Yoshida; H Yamamoto; T Fukuda
Journal:  Eur J Pharmacol       Date:  1982-08-13       Impact factor: 4.432

10.  beta-Endorphin: possible involvement in the antihypertensive effect of central alpha-receptor activation.

Authors:  G Kunos; C Farsang; M D Ramirez-Gonzales
Journal:  Science       Date:  1981-01-02       Impact factor: 47.728

View more
  7 in total

1.  Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension.

Authors:  ShengYu Mu; Tatsuo Shimosawa; Sayoko Ogura; Hong Wang; Yuzaburo Uetake; Fumiko Kawakami-Mori; Takeshi Marumo; Yutaka Yatomi; David S Geller; Hirotoshi Tanaka; Toshiro Fujita
Journal:  Nat Med       Date:  2011-04-17       Impact factor: 53.440

2.  Taurine: A therapeutic agent in experimental kidney disease.

Authors:  H Trachtman; J A Sturman
Journal:  Amino Acids       Date:  1996-03       Impact factor: 3.520

3.  Antihypertensive effects of dietary protein and its mechanism.

Authors:  Sudesh Vasdev; Jennifer Stuckless
Journal:  Int J Angiol       Date:  2010

Review 4.  The potential protective effects of taurine on coronary heart disease.

Authors:  Oktawia P Wójcik; Karen L Koenig; Anne Zeleniuch-Jacquotte; Max Costa; Yu Chen
Journal:  Atherosclerosis       Date:  2009-06-11       Impact factor: 5.162

Review 5.  Kidney and epigenetic mechanisms of salt-sensitive hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2021-02-24       Impact factor: 28.314

Review 6.  Perinatal taurine exposure affects adult arterial pressure control.

Authors:  Sanya Roysommuti; J Michael Wyss
Journal:  Amino Acids       Date:  2012-10-16       Impact factor: 3.520

7.  Aberrant DNA methylation of hypothalamic angiotensin receptor in prenatal programmed hypertension.

Authors:  Fumiko Kawakami-Mori; Mitsuhiro Nishimoto; Latapati Reheman; Wakako Kawarazaki; Nobuhiro Ayuzawa; Kohei Ueda; Daigoro Hirohama; Daisuke Kohno; Shigeyoshi Oba; Tatsuo Shimosawa; Takeshi Marumo; Toshiro Fujita
Journal:  JCI Insight       Date:  2018-11-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.